What is HC Wainwright’s Forecast for Senseonics Q1 Earnings?

Senseonics Holdings, Inc. (NYSE:SENS) – Investment analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Senseonics in a report released on Tuesday, March 3rd. HC Wainwright analyst S. Lee now expects that the company will post earnings of ($0.67) per share for the quarter, down from their previous forecast of ($0.49). HC Wainwright has a “Buy” rating and a $18.50 price objective on the stock. The consensus estimate for Senseonics’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Senseonics’ Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($3.12) EPS, FY2028 earnings at ($2.72) EPS and FY2029 earnings at ($2.03) EPS.

A number of other brokerages also recently issued reports on SENS. Stifel Nicolaus set a $9.00 price target on Senseonics in a research report on Tuesday. TD Cowen reiterated a “buy” rating on shares of Senseonics in a research report on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $22.70.

Senseonics Stock Down 11.1%

Shares of SENS opened at $6.11 on Thursday. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. Senseonics has a 12 month low of $5.25 and a 12 month high of $15.74. The firm’s 50 day moving average is $7.20 and its 200-day moving average is $7.54. The stock has a market capitalization of $255.21 million, a PE ratio of -47.00 and a beta of 0.90.

Institutional Investors Weigh In On Senseonics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Aristides Capital LLC acquired a new position in Senseonics during the 4th quarter worth approximately $139,000. Virtu Financial LLC bought a new stake in shares of Senseonics during the fourth quarter worth $188,000. Quadrature Capital Ltd acquired a new position in shares of Senseonics during the fourth quarter worth $321,000. Balyasny Asset Management L.P. bought a new position in shares of Senseonics in the 4th quarter valued at $91,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Senseonics in the 4th quarter valued at $972,000. 12.36% of the stock is owned by institutional investors.

Senseonics News Roundup

Here are the key news stories impacting Senseonics this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and an $18.50 price target on SENS, which signals the analyst sees upside from current levels despite the cuts to earnings estimates. MarketBeat
• Neutral Sentiment: The same report added a FY2030 EPS forecast (loss of $1.19), giving a longer-term model from the analyst — useful for modeling recovery timing but not an immediate catalyst. MarketBeat
• Negative Sentiment: HC Wainwright cut multiple near-term estimates: Q1 2026 to ($0.67) from ($0.49), Q2 to ($0.72) from ($0.54), Q3 to ($0.78) from ($0.60) and Q4 to ($0.78) from ($0.64). Annual forecasts were also reduced — FY2026 to ($2.95) from ($2.27), FY2027 to ($3.12) from ($2.26), FY2028 to ($2.72) from ($1.88) and FY2029 to ($2.03) from ($1.32). Those deeper loss projections increase downside risk, help explain selling pressure, and could raise the need for additional financing. MarketBeat

About Senseonics

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.